Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Fig 1.

CONSORT diagram of patients.

More »

Fig 1 Expand

Table 1.

Baseline characteristics of the patients in the per-protocol population (n = 54).

More »

Table 1 Expand

Fig 2.

Progression-free survival (PFS) during erlotinib therapy (with 95% CI).

More »

Fig 2 Expand

Fig 3.

Overall survival (OS) of the study population (with 95% CI).

More »

Fig 3 Expand

Table 2.

Ten most frequently reported adverse events.

More »

Table 2 Expand

Fig 4.

Forest plot of hazard ratios (HR) of baseline predictors of overall survival (OS).

More »

Fig 4 Expand

Table 3.

Overview of available outcome data with erlotinib as a second-line treatment.

More »

Table 3 Expand